The Cure Starts Now follows an extensive grant approval process to ensure your dollars make the biggest impact to homerun cancer research. Take comfort in knowing that The Cure Starts Now only funds: research that follows our mission, research that is non-duplicative, and research that is financially sound.


The Cure Starts Now has funded $23,608,247 (USD) in pediatric brain cancer research in partnership with the DIPG / DMG Collaborative. This includes 150 grants at over 100 hospitals in 17 countries.




Cincinnati Children's Hospital – $200,000

Amount
$200,000.00
Date
November 2023

Targeting diffuse midline gliomas with innovative T cell immunotherapy

Cincinnati Children's Hospital – $50,000

Amount
$50,000.00
Date
May 2023

Exploring Novel Targets In DIPG

University Medicine Göttingen – $50,000

Amount
$50,000.00
Date
May 2023

Starve the monster: Multi-metabolic treatment strategies for H3.3K27M-mutant DIPG/DMG

Funding of PBTCF 2023 - $25,000

Amount
$25,000.00
Date
January 2023

University of Queensland Diamantina Institute – $100,000

Amount
$100,000.00
Date
November 2022

Innovative Models of the Brain Microenvironment to Identify New Treatments for Medulloblastoma

Erasmus University Medical Center – $432,354

Amount
$432,354.00
Date
November 2022

Development and optimization of targeted radiopharmaceutical therapies for pediatric brain tumors; a world-first translational study. Acronym: TARGET-FIRST

Cincinnati Children's Hospital Medical Center – $60,000

Amount
$60,000.00
Date
November 2022

Targeting Histone Lysine Demethylases to Treat Diffuse Intrinsic Pontine Glioma

Cincinnati Children's Hospital Medical Center – $153,867

Amount
$153,867.00
Date
November 2022

Combining innovative proton radiotherapy with targeted and immune therapies to treat DMG/DIPG

Hunter Medical Research Institute – $232,932

Amount
$232,932.00
Date
November 2022

Enhancing the recruitment of tumor infiltrating lymphocytes to improve responses to DMG therapies

SONALASENSE – $198,436

Amount
$198,436.00
Date
November 2022

A Phase 1/2 Study of Sonodynamic Therapy Using SONALA-001 and Exablate 4000 Type 2 in Patients With DIPG

UPMC Childrens Hospital of Pittsburgh – $100,000

Amount
$100,000.00
Date
November 2022

The Role of QPRT and NAD Pathways in DIPG Treatment Resistance (Continued)

The Hospital For Sick Children (SickKids) – $100,000

Amount
$100,000.00
Date
November 2022

Synthetic lethality screening with methionine restriction for treatment of DIPG

University of Texas MD Anderson Cancer Center – $100,000

Amount
$100,000.00
Date
November 2022

Viroimmunotherapy for pediatric brain tumors

Hunter Medical Research Institute – $200,000

Amount
$200,000.00
Date
November 2022

DMG COMBATT 2.0: Diffuse Midline Glioma COMbined Anti-Tumor Targeting 2.0

The Institute of Cancer Research – $501,183

Amount
$501,183.00
Date
November 2022

Translating Mechanism to Patient Benefit for ACVR1-Mutant Diffuse Intrinsic Pontine Glioma (DIPG)